Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical ...
The Company will focus resources on advancing its lead asset, PYX-201- PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where ...
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market
New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDermCohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif., Dec. 19 ...